Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Non-Current Liabilities: 2016-2025

Historic Other Non-Current Liabilities for Tg Therapeutics (TGTX) over the last 8 years, with Sep 2025 value amounting to $2.0 million.

  • Tg Therapeutics' Other Non-Current Liabilities fell 36.22% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 36.22%. This contributed to the annual value of $3.8 million for FY2024, which is 961.62% up from last year.
  • Tg Therapeutics' Other Non-Current Liabilities amounted to $2.0 million in Q3 2025, which was down 11.38% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Other Non-Current Liabilities registered a high of $3.8 million during Q4 2024, and its lowest value of $243,000 during Q4 2022.
  • Over the past 3 years, Tg Therapeutics' median Other Non-Current Liabilities value was $2.5 million (recorded in 2024), while the average stood at $2.4 million.
  • In the last 5 years, Tg Therapeutics' Other Non-Current Liabilities tumbled by 61.62% in 2021 and then surged by 961.62% in 2024.
  • Tg Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $360,000 in 2021, then plummeted by 32.50% to $243,000 in 2022, then soared by 46.91% to $357,000 in 2023, then soared by 961.62% to $3.8 million in 2024, then crashed by 36.22% to $2.0 million in 2025.
  • Its Other Non-Current Liabilities stands at $2.0 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.2 million for Q1 2025.